Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003
14/04/2026 15:11
April 14 (Reuters) - Xspray Pharma publ AB XSPRAY.ST: FDA ACCEPTS TRADE NAME NILOPKI FOR XSPRAY'S DRUG CANDIDATE XS003 (NILOTINIB) PLANS US LAUNCH OF NILOPKI AND DASYNOC IN SECOND HALF OF 2026 Source text: ID:nMFNzTcQh Further company coverage: XSPRAY.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003